Comparative mutational analysis of MPAL in recently published large series
| Mutation . | MPAL B-myeloid . | MPAL T-myeloid . | B/T MPAL . | |||
|---|---|---|---|---|---|---|
| Reference . | MDACC21 . | SKACC23 . | SJCCC20 . | SKACC23 . | SJCCC20 . | BCH24 . |
| Number of patients | N = 13 | N = 12 | n = 35 | n = 11 | n = 48 | n = 9 |
| ASXL1 | 3 (23%) | 1 (8%) | - | 1 (9%) | - | 1 (11%) |
| SRSF2 | 3 (23%) | - | - | - | - | 0 |
| TET2 | 2 (15.4%) | 2 (16%) | - | 2 (18%) | - | 0 |
| FLT3 | 3 (23%) | 0 | 6 (17%) | 2 (18%) | 21 (44%) | 0 |
| CEBPA | 0 | 1 (8%) | 0 | 1 (9%) | 5 (10.4%) | 0 |
| RUNX1 | 6 (46%) | 1 (8%) | 8 (23%) | 1 (9%) | 3 (6%) | 1 (11%) |
| PTNP11 | 1 (7.7%) | 0 | 6 (17%) | 0 | 4 (8.3%) | 2 (22%) |
| ZNF384 | 0 | 0 | 15 (43%) | 0 | 0 | |
| NOTCH1 | 0 | 1 (8%) | 0 | 0 | 8 (17%) | 1 (11%) |
| WT1 | 1 (7.7%) | 1 (8%) | 2 (6%) | 3 (27%) | 20 (41%) | 1 (11%) |
| PHF6 | 0 | 1 (8%) | 1 (3%) | 2 (18%) + 3 (27%) | 0 | 5 (55%) |
| DNMT3A | 1 (7.7%) | 0 | - | 4 (36%) | - | 1 (11%) |
| ETV6 | 0 | 0 | 8 (23%) | 2 (18%) | 12 (25%) | 2 (22%) |
| NRAS | 3 (23%) | 1 (8%) | 11 (31%) | 2 (18%) | 4 (8.3%) | 0 |
| KRAS | 0 | 2 (16%) | 3 (8.5%) | 2 (16%) | 3 (6%) | 0 |
| TP53 | 1 (7.7%) | 0 | 2 (6%) | 2 (18%) | 0 | 2 (22%) |
| Mutation . | MPAL B-myeloid . | MPAL T-myeloid . | B/T MPAL . | |||
|---|---|---|---|---|---|---|
| Reference . | MDACC21 . | SKACC23 . | SJCCC20 . | SKACC23 . | SJCCC20 . | BCH24 . |
| Number of patients | N = 13 | N = 12 | n = 35 | n = 11 | n = 48 | n = 9 |
| ASXL1 | 3 (23%) | 1 (8%) | - | 1 (9%) | - | 1 (11%) |
| SRSF2 | 3 (23%) | - | - | - | - | 0 |
| TET2 | 2 (15.4%) | 2 (16%) | - | 2 (18%) | - | 0 |
| FLT3 | 3 (23%) | 0 | 6 (17%) | 2 (18%) | 21 (44%) | 0 |
| CEBPA | 0 | 1 (8%) | 0 | 1 (9%) | 5 (10.4%) | 0 |
| RUNX1 | 6 (46%) | 1 (8%) | 8 (23%) | 1 (9%) | 3 (6%) | 1 (11%) |
| PTNP11 | 1 (7.7%) | 0 | 6 (17%) | 0 | 4 (8.3%) | 2 (22%) |
| ZNF384 | 0 | 0 | 15 (43%) | 0 | 0 | |
| NOTCH1 | 0 | 1 (8%) | 0 | 0 | 8 (17%) | 1 (11%) |
| WT1 | 1 (7.7%) | 1 (8%) | 2 (6%) | 3 (27%) | 20 (41%) | 1 (11%) |
| PHF6 | 0 | 1 (8%) | 1 (3%) | 2 (18%) + 3 (27%) | 0 | 5 (55%) |
| DNMT3A | 1 (7.7%) | 0 | - | 4 (36%) | - | 1 (11%) |
| ETV6 | 0 | 0 | 8 (23%) | 2 (18%) | 12 (25%) | 2 (22%) |
| NRAS | 3 (23%) | 1 (8%) | 11 (31%) | 2 (18%) | 4 (8.3%) | 0 |
| KRAS | 0 | 2 (16%) | 3 (8.5%) | 2 (16%) | 3 (6%) | 0 |
| TP53 | 1 (7.7%) | 0 | 2 (6%) | 2 (18%) | 0 | 2 (22%) |